Techcyte
Techcyte builds Fusion, a cloud-based AI platform that unifies anatomic and clinical pathology workflows using deep learning on whole-slide images. It serves human clinical labs, veterinary clinics (via Zoetis), environmental testing labs, and food safety markets.
- Company typePrivate
- Founded2013
- HeadquartersOrem, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Techcyte does
Techcyte is a digital pathology AI company founded in 2013 as a technology transfer from the University of Utah and headquartered in Orem, Utah. The company builds Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic pathology (AP) and clinical pathology (CP) workflows into a single workspace, addressing a market historically served by fragmented, single-purpose tools. Techcyte's core AI is built on proprietary deterministic convolutional neural networks trained to detect, classify, and count diagnostic objects (parasites, blood cells, bacteria, cervical cells, and pathology structures) on whole-slide microscopy images, validated with quantified accuracy metrics ranging from 95% to 98.9% in published studies. The platform is DICOM-native, supports all major WSI scanner formats, uses a microservices architecture on AWS, and integrates with LIS/EHR/PACS systems via HL7, FHIR, and DICOMweb standards.
The company operates across four verticals: human clinical pathology (parasitology, bacteriology, hematology, cervical cytology via SureView), veterinary diagnostics (embedded as the AI engine for Zoetis's Vetscan Imagyst platform), environmental testing (Sporecyte brand for mold and air quality), and food safety (Stericyte brand launched 2025). Revenue is generated through multi-year SaaS subscriptions, OEM/embedded licensing royalties (notably from Zoetis, where Techcyte AI powered 3M+ scans by 2024), professional services, and scanner distribution partnerships. Distribution combines direct enterprise sales, exclusive OEM partnerships (Zoetis for veterinary, BD for cervical cytology), and an ESP (Expert Solution Provider) international channel program. The company has raised approximately $36M+ across seed rounds, a 2021 Series E led by Zoetis, and a 2026 capital raise led by Van Tuyl Companies, with the veterinary segment already profitable and human/environmental segments targeting profitability by 2027.
Techcyte firmographics
Firmographics- Name
- Techcyte
- Legal name
- Techcyte, Inc.
- Website
- https://techcyte.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Techcyte builds Fusion, a cloud-based AI platform that unifies anatomic and clinical pathology workflows using deep learning on whole-slide images. It serves human clinical labs, veterinary clinics (via Zoetis), environmental testing labs, and food safety markets.
- Ownership category
- akta.pro rank
Techcyte industry classification
Industry- Product category
- Digital Pathology AI Software
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Techcyte is headquartered
LocationHeadquarters
- HQ city
- Orem
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Techcyte business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Subscription/SaaS: Recurring subscription-based revenue from hosted SaaS access to Techcyte Fusion and related AI suites. Customers must sign subscription agreements to use the platform (per ESP portal terms). Includes ESP (Expert Solution Provider) international distribution tier.
- Scanner distribution / hardware resale: Techcyte acts as a trusted distributor of top whole-slide scanners (Hamamatsu, 3DHistech, Pramana, Motic, Grundium, MetaSystems), generating revenue from hardware sales or referral arrangements to support its platform deployments.
- OEM/embedded licensing (Zoetis Vetscan Imagyst): Techcyte AI algorithms are embedded within Zoetis's Vetscan Imagyst platform — generating royalty/licensing revenue per test analyzed. Surpassed 3 million digital scans across Zoetis platform (2024) and over 2 million scans by 2023.
- Professional services / implementation: Implementation, training, onboarding, scanner consultation, and ongoing support services delivered alongside platform deployments; supported by in-app training and dedicated account management.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Custom enterprise subscription |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels9 records
Techcyte product offering
Product offeringCore offering
Techcyte sells Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic and clinical pathology workflows by combining whole-slide imaging, deterministic convolutional neural network AI inference, intelligent worklists, synoptic reporting, and LIS/EHR integration. The platform is sold as modules (Fusion AP, Frozen Section, SureView Cervical Cytology, Parasitology, Bacteriology, Hematology, Organ Donation) plus the Sporecyte environmental mold testing brand, deployed to hospital systems, reference labs, and academic medical centers, with embedded AI delivered through the Zoetis Vetscan Imagyst OEM partnership.
Differentiator
Problem solved
Functional benefit
Brands
- Vetcyte: AI-powered digital diagnostics platform for the veterinary industry, originally split out as a separate brand in 2016; powers VETSCAN IMAGYST in partnership with Zoetis.
- Sporecyte
- Stericyte
- Techcyte Fusion
- Techcyte SureView
Products and services
- Techcyte Fusion The unified anatomic and clinical pathology AI platform — a cloud-native, browser-based, SaaS-delivered workspace built on AWS with microservices and REST APIs that integrates whole-slide scanning, AI inference (Techcyte-built and 3rd-party via the Fusion Partner Program), intelligent worklist, ultra-fast slide viewer, synoptic reporting, LIS/EHR integration, and DICOMweb interoperability. Sells the Fusion AP, Fusion Frozen Section Suite, Fusion Parasitology Suite, Fusion Bacteriology Suite, Fusion Hematology Suite, Fusion Organ Donation Suite, and SureView Cervical Cytology System under one platform.
- Fusion AP Fusion Anatomic Pathology module supporting surgical pathology, cytology, dermatopathology, frozen section, breast, prostate, GI, non-GYN cytology, and renal workflows. Provides an ultra-fast multi-monitor slide viewer (up to 6 co-registered images), intelligent worklist with case routing/prioritization, in-app messaging, synoptic reporting, and integrated 3rd-party AI through the Fusion Partner Program (Aiforia, Aiosyn, Mindpeak, Modella AI, Deep Bio, Aira Matrix, BIOBASE, Voicebrook, Dolbey). For research use only in the US; CE-IVDR marked in the EU.
- Fusion Frozen Section Suite Digital workflow for frozen section labs that integrates Grundium Ocus 40 and Pramana Spectral-M scanners to digitize frozen section slides, route cases to pathologists, enable remote consultation, and deliver real-time intra-operative results to surgeons in the OR via a dedicated OR view. For research use only and not for diagnostic use in the US.
- Techcyte SureView Cervical Cytology System
Companies that use Techcyte
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles5 records
Techcyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration29 records
AI capability10 records
Feature7 records
Techcyte partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core, flagship and minor.
- Aira MatrixcoreTechcyte integrated Aira Matrix AI into the Fusion AP digital pathology platform for prostate pathology AI; demonstrated in Episode 26 of Pioneers in Digital Pathology webinar series (April 2026).
- VoicebrookcoreAdded to Techcyte Fusion Partner Program in March 2026, integrating voice-enabled workflow capabilities into the Techcyte Fusion digital pathology platform — enables pathologists to navigate cases, complete CAP reporting, and execute operational tasks via voice commands.
- BiobasecoreBiobase and Techcyte partnered to advance digital pathology and unlock the full potential of clinical data. Biobase is a Fusion Partner Program member.
- Modella AIcoreResearch collaboration announced August 2025 with Modella AI's state-of-the-art agentic and generative AI-powered diagnostic pathology platform integrated into Techcyte Fusion.
- Deep BiocoreJoined Techcyte Fusion Partner Program in August 2025 to integrate AI-powered prostate diagnostics and frozen section capabilities into the Fusion platform.
- Mindpeak GmbHcoreGermany-based Mindpeak partnered with Techcyte in July 2025 to integrate Mindpeak's explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics. Joined Techcyte Fusion Partner Program.
- AiforiacoreStrategic collaboration announced March 2025 to advance AI-powered digital pathology. Aiforia's AI models are integrated into the Fusion Partner Program for anatomic pathology workflows.
- AiosyncoreCollaboration announced March 2025 to integrate AI-powered slide QC and mitotic counting into the Fusion digital pathology platform. Part of a three-way Techcyte/Pramana/Aiosyn Edge AI collaboration also announced in March 2025.
- PramanacoreThree-way collaboration with Techcyte, Pramana, and Aiosyn announced March 2025 to advance digital pathology workflow with edge AI technology. Pramana Spectral-M Pro/HT2/HT4 scanners are supported across Techcyte's product lines.
- Mayo Clinic PlatformflagshipStrategic collaboration announced January 2024 to create an open, standards-based, AI-enabled comprehensive digital pathology platform (Fusion AP). Co-developed and validated the Fusion Bacteriology Suite (Gram stain). Mayo Clinic is also an investor (participated in $15M raise in 2026) and provides access to Safe Harbor dataset of 17M+ de-identified slides.
- BD (Becton, Dickinson and Company)flagshipStrategic collaboration announced January/February 2024 with BD granted worldwide distribution of the AI-Based Digital Cervical Cytology System (Techcyte SureView). Collaboration addresses global shortage of skilled cytotechnologists.
- CompuMedcoreCompuMed integrated Techcyte Digital Pathology Platform to enhance digital manual review of available livers and kidneys for organ transplant availability (October 2023).
- ARUP LaboratoriesflagshipEarly collaborator and customer. Strategic partnership and investment established in 2018. Co-developed AI-based solutions for trichrome, modified acid fast, and wet mount iodine parasitology tests. Deployed world's first AI-augmented ova and parasite detection tool in 2019. Released fecal wet mount iodine solution with ARUP in 2025.
- Ketterthill (Luxembourg)minorStrategic partnership established in 2018 — Techcyte partner for the BV Gram stain solution and clinical pathology in Luxembourg.
- ZoetisflagshipExclusive veterinary partner producing Vetscan Imagyst — Techcyte AI is embedded across fecal O&P, FNA, blood smears, dermatology, urine sediment, AI Masses cytology, equine tests. Surpassed 2 million tests (2023) and 3 million digital scans (2024) across the platform. Led Techcyte's $21M Series E in 2021 and participated in the 2026 $15M raise. Zoetis is the world's largest producer of veterinary medicine.
- MoticcoreStrategic partnership and investment from Motic (2017). Motic scanners (Motic EasyScan One/Pro/Infinity) are supported across Techcyte product lines.
- University of UtahflagshipTechcyte began as a technology transfer from the University of Utah in 2013. Founders Ralph Yarro and Rick Smith licensed a white-paper on white blood cell classification from Dr. Mohamed Salama. New study (Feb 2023) demonstrated value of AI in organ transplantation; donated to U of U Transplant Buddy Fund (May 2022).
Scale indicators12 records
Recent moves8 records
Expansion highlights7 records
Techcyte competitors and assessment
Company assessmentDirect peers
- Proscia: Cloud-based digital pathology platform combining whole-slide image management with AI applications for biopharma, reference labs, and academic centers. Highly comparable to Techcyte Fusion in target customer, SaaS delivery model, and use of third-party AI integrations.
- PathAI: AI-powered pathology platform offering diagnostic AI for pharma services, clinical research, and diagnostic applications including oncology and IBD. Overlaps directly with Techcyte Fusion AP and SureView in anatomic/clinical pathology AI and uses similar deep-learning approaches on whole-slide images.
- Paige.AI: AI-native digital pathology company focused on cancer detection across prostate, breast, and other tumor types with FDA-cleared prostate AI. Directly comparable in AI capability type (CNN-based tumor detection on whole-slide images), target customer (academic medical centers, reference labs), and pathology category.
- Ibex Medical Analytics: AI platform for cancer diagnostics deployed in clinical pathology workflows for breast, prostate, and GI biopsies with CE-marked and Galen platform. Closely comparable to Techcyte SureView and Fusion AP in use case, target lab customer, and clinical-grade AI deployment.
- Aiforia: Cloud-based AI image analysis platform for pathology and other life-science imaging with a deep-learning model development environment. Both a Fusion Partner Program member and direct peer in AP AI workflows serving academic medical centers and pharma.
- Indica Labs: Provider of HALO digital pathology image analysis software and AI/deep-learning toolkits used by pharma, CROs, and research pathology labs. Comparable to Techcyte Fusion in AP use cases, image-management stack, and AI module ecosystem.
- Visiopharm: AI-driven digital pathology software (Phenoptics, Oncotopix) for research and clinical workflows including cancer diagnostics. Comparable AP AI offering and target customers in pharma and clinical research.
Broad incumbents
- Philips (Philips Digital Pathology): Owner of IntelliSite Pathology Solution — an enterprise digital pathology platform with whole-slide scanners, image management, and AI ecosystem including iSyntax. Broader portfolio player with deeper hospital relationships than Techcyte; same AP end-user segment and DICOM/PACS-style integration.
- Roche (VENTANA / Roche Digital Pathology): Operates the uPath digital pathology platform combined with VENTANA slide scanners and staining systems and a broad companion-diagnostic AI portfolio. Direct overlap with Techcyte Fusion AP, SureView, and the partner-AI model; major incumbent competitor and potential partner/customer.
- Leica Biosystems (Danaher): Provider of Aperio digital pathology scanners and software widely deployed across hospital systems and academic centers. Comparable AP/CP use cases and whole-slide image formats (SVS); entrenched incumbent in the same customer base as Techcyte.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Techcyte social profiles
Digital presenceTechcyte compliance and trust
Trust signalCompliance8 records
Techcyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
Techcyte leadership team
Management profileNumber of profiles
Profiles17 records
Techcyte subsidiaries and ownership
Company hierarchySubsidiaries3 records
Techcyte funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Techcyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Techcyte
What does Techcyte do?
Techcyte sells Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic and clinical pathology workflows by combining whole-slide imaging, deterministic convolutional neural network AI inference, intelligent worklists, synoptic reporting, and LIS/EHR integration. The platform is sold as modules (Fusion AP, Frozen Section, SureView Cervical Cytology, Parasitology, Bacteriology, Hematology, Organ Donation) plus the Sporecyte environmental mold testing brand, deployed to hospital systems, reference labs, and academic medical centers, with embedded AI delivered through the Zoetis Vetscan Imagyst OEM partnership.
Is Techcyte a public or private company?
Techcyte is a private company. It is classified as venture growth investor backed and is currently operating.
When was Techcyte founded?
Techcyte was founded in 2013. It employs 101 to 250 people.
Where is Techcyte based?
Techcyte is headquartered in Orem, United States, in the North America region.
How does Techcyte make money?
Four revenue lines are on record. Subscription/SaaS are the primary driver. The others are scanner distribution / hardware resale, OEM/embedded licensing (Zoetis Vetscan Imagyst) and professional services / implementation.
Who are Techcyte's main competitors?
Direct peers on record are Proscia, PathAI, Paige.AI, Ibex Medical Analytics, Aiforia, Indica Labs and Visiopharm. Broad incumbents are Philips (Philips Digital Pathology), Roche (VENTANA / Roche Digital Pathology) and Leica Biosystems (Danaher).
Does Techcyte have an API?
Yes. Techcyte Fusion is built using a microservices architecture and exposes REST APIs (described as "RESTless APIs") for platform integration. A complete, documented API enables integration with laboratory information systems (LIS), electronic health records (EHR), grossing stations, and radiology systems. The platform also supports DICOMweb access to whole slide image archives (query/fetch on-demand) and integrates with the Techcyte Connect Uploader for ingesting DICOM ZIP outputs from whole slide scanners. Fusion is deployed on AWS for global scalability, uses the OAuth framework with Auth0 for role-based SSO, and is DICOM-first by design. The Fusion Partner Program also exposes a unified third-party AI API for integrating partner algorithms into Fusion Anatomic Pathology workflows.
What industry is Techcyte in?
Techcyte's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334516 and its SIC code is 3841.